Despite the promise of prostate-specific membrane antigen (PSMA) uptake, it is not completely specific to prostate cancer (PCa), with reports of uptake in benign and non-PCa malignancies as well (1–3). This evidence concerns the gene FOLH1 and Familial prostate cancer.